Background: Limited data are available for test utilization and intraindividual changes in anti-thyroid peroxidase antibodies (anti-TPO Ab) in Korean patients.

Methods: Using a laboratory information system, we retrospectively investigated longitudinally measured anti-TPO Ab along with thyroid function test (TFT) in Korean patients visiting local clinics.

Results: During the two-year study period, 542 test results from 183 Korean patients were requested from 51 local clinics and hospitals. Among all 183 patients, 94 (51.4%) exhibited positive anti-TPO Ab (> 34 IU/mL) at initial measurement. Among them, 13.8% (13/94) changed to negative anti-TPO Ab at least once during follow-up. Among 89 patients with initial negative anti-TPO Ab result, five (5.6%) changed to positive anti-TPO Ab at least once during follow up.

Conclusions: Some patients exhibited qualitative changes in anti-TPO Ab. Future studies are needed to clarify the clinical implication of such changes.

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2021.201227DOI Listing

Publication Analysis

Top Keywords

korean patients
12
anti-thyroid peroxidase
8
local clinics
8
clinics hospitals
8
intraindividual changes
8
positive anti-tpo
8
negative anti-tpo
8
anti-tpo
7
patients
6
utilization anti-thyroid
4

Similar Publications

Objective: Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening is safe and potentially beneficial in patients with Alzheimer's disease (AD) for the removal of amyloid-beta (Aβ) plaques. However, the optimal BBB opening intervals and number of treatment sessions for clinical improvement remain undefined. Therefore, the aim of this study was to evaluate the safety and benefits of repeated and more extensive BBB opening alone.

View Article and Find Full Text PDF

While acute upper gastrointestinal bleeding (AUGIB) remains clinically critical, the etiology of bleeding and risk factors for mortality remain uncertain. This study aimed to evaluate the underlying causes of AUGIB and identify risk factors associated with fatality. A retrospective survey was conducted in a major clinical hospital in Shanghai, where inpatients diagnosed with AUGIB were meticulously collected and analyzed.

View Article and Find Full Text PDF

Background: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.

Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.

View Article and Find Full Text PDF

Interferon-gamma (IFN-γ) autoantibody syndrome is an emerging clinical entity that has been associated with disseminated non-tuberculous mycobacterial infection (dNTM) particularly in healthy young people, a population not previously thought to be at particular risk. A 29-year-old South-East Asian man presented with several weeks of fever, cough, lymphadenopathy, and constitutional symptoms while working on an international cargo ship, deteriorating rapidly with a sepsis-like syndrome. Eventually lymph node and sputum cultures revealed a diagnosis of dNTM infection with growth of both Mycobacterium persicum and Mycobacterium abscessus.

View Article and Find Full Text PDF

Over the past few decades, dental implants have been successfully utilized to replace teeth lost due to periodontal disease and other conditions. However, similar to natural teeth, dental implants are vulnerable to inflammatory peri-implant diseases, which can compromise their long-term viability. This review aims to summarize the current understanding of peri-implant diseases and discuss effective strategies for their diagnosis, treatment, and long-term management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!